Nadeem Riaz (@xrtGenomics) / X

Nadeem Riaz

2,108 posts

Nadeem Riaz

@xrtGenomics

Physician/Scientist. Head and Neck Oncologist (radiation). Interests in cancer genomics, immunotherapy & DNA repair. @MSKCancerCenter

New York, NY

Joined May 2009

Pinned
Nadeem Riaz
@xrtGenomics
Jan 5
🥳🎆 Kicking of 2026 with our work showing intra-tumoral bacteria 🦠 affect outcomes of Radiotherapy + anti-PD-L1 now out in @NatureCancer with sister paper by @nataliesilvermd! Even when trials "fail" – we can learn from them! nature.com/articles/s4301…. -- w/ @GeneCollector,
7.7K
Nadeem Riaz
@xrtGenomics
Jan 19, 2024
1/N Finally out!! -- 30Gy for HPV+OPC in @JCO_ASCO – work by the @MSKCancerCenter Head and Neck team, led by @imrtlee, Eric Sherman, and myself on using hypoxia imaging response to cut treatment 60% (70->30Gy)! #radonc #hncsm
ascopubs.org
Hypoxia-Directed Treatment of Human Papillomavirus–Related Oropharyngeal Carcinoma
PURPOSEStandard curative-intent chemoradiotherapy for human papillomavirus (HPV)–related oropharyngeal carcinoma results in significant toxicity. Since hypoxic tumors are radioresistant, we posited...
68K
Nadeem Riaz
@xrtGenomics
Nov 16, 2020
Finally out! Our work on BRCA1 & BRCA2 have distinct effects on cancer immunity in mice & people. Led by phys-sci superstar @rsamstein, grad-student wonder @chirag_msk, the amazing Xiaoxiao, with tutelage from jedimaster @GeneCollector, & help of many nature.com/articles/s4301… 1/N
Nadeem Riaz
@xrtGenomics
Jan 12, 2021
Out now in @JNCI_now (academic.oup.com/jnci/advance-a…)! @sloan_kettering H&N team’s work on Precision Radiotherapy for HPV+ HNSCC: **30Gy** for definitive treatment! Spear-headed by @imrtlee & Eric Sherman, & and an all-star translational cast (JRF, SNP, TC, & more). #radonc #hncsm (1/N)
Nadeem Riaz
@xrtGenomics
Nov 14, 2023
PACIFIC 2 is negative (CCRT+Durva --> adjvuant durva vs. CCRT alone); remarkable when PACIFIC 1 (+/- adjuvant durva) was very positive, very quickly. Another suggestion concurrent RT + IO may have a negative interaction? #radonc #lcsm
astrazeneca.com
Update on PACIFIC-2 Phase III trial of Imfinzi concurrently administered with platinum-based...
21K
Nadeem Riaz
@xrtGenomics
May 3, 2023
Uh oh... 26% rate of elective failure from SBRT + Durva/Tremi + surgery in HPV+ HNSCC targetting only gross disease. Definitely needs some caution with this. redjournal.org/article/S0360-…. @imrtlee @sueyom @CJTsaiMDPhD @seanmmcbride h/t Narek
23K
Nadeem Riaz
@xrtGenomics
Jul 20, 2022
Wow -- fourth large concurrent CRT/IO study negative (3rd one in HNSCC; one in cervix). Time for a re-think here? #radonc #hncsm @GeneCollector @imrtlee @rweichselbaum @HenningWillers @seanmmcbride @jdschoenfeld1 @DrHaddadRobert @sueyom
businesswire.com
Merck Provides Update on Phase 3 KEYNOTE-412 Trial in Unresected Locally Advanced Head and Neck...
Merck Provides Update on Phase 3 KEYNOTE-412 Trial in Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma
Nadeem Riaz
@xrtGenomics
Feb 8, 2023
Wow -- another de-escalation study in HPV+ HNSCC negative. I think many people thought this would do the trick. Clearly, can not de-escalate all comers in HPV+ OPC.
NRG Oncology
@NRGonc
Feb 8, 2023
NRG-HN005 results of scheduled interim futility analysis comparing experimental arm to control arm for randomized phase II portion of the study showed that the experimental arm didn't achieve non-inferiority threshold per statistical analysis plan. conta.cc/3DRvsu2
38K
Nadeem Riaz
@xrtGenomics
Mar 24, 2022
CALLA (Durva+CRT) in cervix -- NEGATIVE! That's 2 of 2 large RCTs studying concurrent CRT+ICB that are negative now (other being javelin, @imrtlee). Several smaller studies also suggesting some detriment to concurrent. Maybe adjuvant alone is the future?
astrazeneca.com
Update on CALLA Phase III trial of concurrent use of Imfinzi and chemoradiotherapy in locally...
Nadeem Riaz
@xrtGenomics
Jun 3, 2022
Great talk by @sueyom on cfDna in hpv cancers from hn002. Cfdna detectable in 90%; 3 week intra treatment has variable kinetics; nearly predicts outcomes shortly after rt; #asco22 #hncsm @NRGonc
Nadeem Riaz
@xrtGenomics
Mar 30, 2021
The first read-out of concurrent chemo-RT+anti-PD1/PD-L1 in HNSCC -- led by H&N dream team of @imrtlee @RobertFerrisMD , and @DrEzraCohen. Disappointingly a NEGATIVE study! and maybe some evidence of harm? (1/N)
Nadeem Riaz
@xrtGenomics
Jul 26, 2023
It amazes me that anonymized individual patient-level data is not required as a supplemental table for clinical studies STILL in 2023. There is no real good reason against providing show raw data for what is published.
nature.com
Medicine is plagued by untrustworthy clinical trials. How many studies are faked or flawed?
Nature - Investigations suggest that, in some fields, at least one-quarter of clinical trials might be problematic or even entirely made up, warn some researchers. They urge stronger scrutiny.
3.7K
Nadeem Riaz
@xrtGenomics
Sep 21, 2020
Interesting data at #ESMO2020 -- suggesting RT+Anti-PD1 concurrently may not be straight forward. JAVELIN HNSCC negative for CRT+/-Avelumab; Small GORTEC study showing no improvement in outcomes with Pembro vs. Cetux (low bar!).Concurrent the wrong direction? Or too early yet?
Nadeem Riaz
@xrtGenomics
Jun 3, 2022
Important data from David Clump and Pitt tream suggesting (trend) concurrent anti-pd1 with rt may be inferior to sequential treatment in #hncsm @imrtlee #radonc #ASCO2022